The new trend in this study is the implication of nitazoxanide and escitalopram as anti-inflammatory and immunomodulatory adjuvant therapy for patients with RA, through their suggested interruption of the STAT-3/JAK-2 signaling pathway, TLR-4/IL-1β signaling pathway, and their ability to modulate oxidative stress. The gene discussed is STAT3; the disease is rheumatoid arthritis.